Search

Displaying results 5381 - 5390 of 10000 in total
  1. Drug

    Endralazine

    go.drugbank.com/drugs/DB13435
    Experimental

    Categories: Arteriolar Smooth Muscle, Agents Acting On
  2. Drug

    Fluocortin

    go.drugbank.com/drugs/DB13223
    Experimental

    Fluocortin has been studied as a corticosteroid for treatment of dermatitis and eczema Spain .

    Categories: Corticosteroids, Moderately Potent (Group II)
  3. Drug

    Fluperolone

    go.drugbank.com/drugs/DB13491
    Experimental

    Categories: Corticosteroids, Moderately Potent (Group II)
  4. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    It acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors. … It provides anti-psychotic characteristic and a low incidence of extrapyramidal and cardiovascular side effects.

  5. Drug

    Polistes exclamans venom protein

    go.drugbank.com/drugs/DB11028
    Approved

    Polistes exclamans venom protein is an extract of Polistes exclamans venom. Polistes exclamans venom protein is used in allergenic testing.

  6. Drug

    Vespula pensylvanica venom protein

    go.drugbank.com/drugs/DB11031
    Approved

    Vespula pensylvanica venom protein is an extract of Vespula pensylvanica venom. Vespula pensylvanica venom protein is used in allergenic testing.

  7. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    Oftasceine is also referred to as Fluorexon. It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.

  8. Drug

    T487

    go.drugbank.com/drugs/DB05474
    Experimental

    The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. … T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3.

  9. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

    Synonyms: L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, ACETATE (1:2), L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, DIACETATE
  10. Drug

    IGN311

    go.drugbank.com/drugs/DB04988
    Experimental

    IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.